tetano
Editor, Senior Moderator
Int J Infect Dis
. 2021 Apr 14;S1201-9712(21)00345-3.
doi: 10.1016/j.ijid.2021.04.035. Online ahead of print.
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
Raymond Chee Seong Seet[SUP] 1 [/SUP], Amy May Lin Quek[SUP] 2 [/SUP], Delicia Shu Qin Ooi[SUP] 3 [/SUP], Sharmila Sengupta[SUP] 4 [/SUP], Satish Ramapatna Lakshminarasappa[SUP] 5 [/SUP], Chieh Yang Koo[SUP] 6 [/SUP], Jimmy Bok Yan So[SUP] 7 [/SUP], Boon Cher Goh[SUP] 8 [/SUP], Kwok Seng Loh[SUP] 9 [/SUP], Dale Fisher[SUP] 10 [/SUP], Hock Luen Teoh[SUP] 2 [/SUP], Jie Sun[SUP] 11 [/SUP], Alex R Cook[SUP] 11 [/SUP], Paul Anantharajah Tambyah[SUP] 10 [/SUP], Mikael Hartman[SUP] 12 [/SUP]
Affiliations
Abstract
Background: We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19).
Methods: An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined as individual floors of the dormitory) were randomly assigned to receive a 42-day prophylaxis regimen of either oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 ?g/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral vitamin C, 500 mg/day. The primary outcome was laboratory evidence of SARS-CoV-2 infection as shown by either: (1) a positive serologic test for SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at any time between baseline and day 42.
Results: A total of 3,037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the primary analysis. Follow-up was nearly complete (99.6%). Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2-42%) and povidone-iodine throat spray (24%, 7-39%). No statistically significant differences were observed with oral zinc/vitamin C combination (23%, -5 to +41%) and ivermectin (5%, -10 to +22%). Interruptions due to side effects were highest among participants who received zinc/vitamin C combination (6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%) and hydroxychloroquine (0.7%).
Conclusions: Chemoprophylaxis with either oral hydroxychloroquine or povidone-iodine throat spray was superior to oral vitamin C in reducing SARS-CoV-2 infection in young and healthy men. CLINICALTRIALS.
Gov number: NCT04446104.
Keywords: Hydroxychloroquine; SARS-CoV-2; ivermectin; povidone-iodine; vitamin C; zinc.
. 2021 Apr 14;S1201-9712(21)00345-3.
doi: 10.1016/j.ijid.2021.04.035. Online ahead of print.
Positive impact of oral hydroxychloroquine and povidone-iodine throat spray for COVID-19 prophylaxis: an open-label randomized trial
Raymond Chee Seong Seet[SUP] 1 [/SUP], Amy May Lin Quek[SUP] 2 [/SUP], Delicia Shu Qin Ooi[SUP] 3 [/SUP], Sharmila Sengupta[SUP] 4 [/SUP], Satish Ramapatna Lakshminarasappa[SUP] 5 [/SUP], Chieh Yang Koo[SUP] 6 [/SUP], Jimmy Bok Yan So[SUP] 7 [/SUP], Boon Cher Goh[SUP] 8 [/SUP], Kwok Seng Loh[SUP] 9 [/SUP], Dale Fisher[SUP] 10 [/SUP], Hock Luen Teoh[SUP] 2 [/SUP], Jie Sun[SUP] 11 [/SUP], Alex R Cook[SUP] 11 [/SUP], Paul Anantharajah Tambyah[SUP] 10 [/SUP], Mikael Hartman[SUP] 12 [/SUP]
Affiliations
- PMID: 33864917
- DOI: 10.1016/j.ijid.2021.04.035
Abstract
Background: We examined whether existing licensed pharmacotherapies could reduce the spread of coronavirus disease 2019 (COVID-19).
Methods: An open-label parallel randomized controlled trial was performed among healthy migrant workers quarantined in a large multi-storey dormitory in Singapore. Forty clusters (each defined as individual floors of the dormitory) were randomly assigned to receive a 42-day prophylaxis regimen of either oral hydroxychloroquine (400 mg once, followed by 200 mg/day), oral ivermectin (12 mg once), povidone-iodine throat spray (3 times/day, 270 ?g/day), oral zinc (80 mg/day)/vitamin C (500 mg/day) combination, or oral vitamin C, 500 mg/day. The primary outcome was laboratory evidence of SARS-CoV-2 infection as shown by either: (1) a positive serologic test for SARS-CoV-2 antibody on day 42, or (2) a positive PCR test for SARS-CoV-2 at any time between baseline and day 42.
Results: A total of 3,037 asymptomatic participants (mean age, 33.0 years; all men) who were seronegative to SARS-CoV-2 at baseline were included in the primary analysis. Follow-up was nearly complete (99.6%). Compared with vitamin C, significant absolute risk reductions (%, 98.75% confidence interval) were observed for oral hydroxychloroquine (21%, 2-42%) and povidone-iodine throat spray (24%, 7-39%). No statistically significant differences were observed with oral zinc/vitamin C combination (23%, -5 to +41%) and ivermectin (5%, -10 to +22%). Interruptions due to side effects were highest among participants who received zinc/vitamin C combination (6.9%), followed by vitamin C (4.7%), povidone-iodine (2.0%) and hydroxychloroquine (0.7%).
Conclusions: Chemoprophylaxis with either oral hydroxychloroquine or povidone-iodine throat spray was superior to oral vitamin C in reducing SARS-CoV-2 infection in young and healthy men. CLINICALTRIALS.
Gov number: NCT04446104.
Keywords: Hydroxychloroquine; SARS-CoV-2; ivermectin; povidone-iodine; vitamin C; zinc.